Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or a left ventricular assist device (LVAD).

Ochsner Children's Hospital, ranked among the top hospitals in the nation for pediatric cardiology and congenital heart surgery, is raising awareness of the need for more pediatric-specific heart devices

News | Pediatric Cardiology

Ochsner Children’s Hospital Advocates to Close the Gap in Pediatric Heart Care

February 21, 2024 — Ochsner Children's Hospital, ranked among the top hospitals in the nation for pediatric cardiology a ...

February 21, 2024

The Medtronic APOLLO Clinical Trial is evaluating the safety and efficacy of an investigative device called the Intrepid Transcatheter Mitral Valve Replacement System (TMVR) for moderate-to-severe or severe symptomatic mitral regurgitation (MR) in patients who may be unsuitable for approved transcatheter repair or surgery.

News | Structural Heart

Hackensack Meridian Jersey Shore University Medical Center Providing State-of-the-Art Medtronic APOLLO Clinical Trial Treating Heart Valve Disease

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an ...

February 20, 2024

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF).

News | Cardiovascular Clinical Studies

First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

February 15, 2024

Sponsored Content

Blog | Artificial Intelligence

BLOG: AI outperforms human analysis in predicting cardiac outcomes

New research shows superiority of Ultromics’ AI in predicting cardiac-related death As the use of artificial ...

October 10, 2022

Research findings in a clinical trial led by a professor at the University of Tennessee Health Science Center’s College of Nursing are likely to dramatically change care and improve outcomes for patients suffering from acute stroke.

News | Stroke

ZODIAC Clinical Trial Led by UT Health Science Center Professor Likely to Make Major Impact on Stroke Care

February 15, 2024 — Research findings in a clinical trial led by a professor at the University of Tennessee Health ...

February 15, 2024

The limited clinical trial represents the first human implantation of a cardiac auscultation sensor device

News | Heart Failure

Canary Completes First-in-Human Trial of Cardiac Auscultation Monitoring Sensor

February 15, 2024 — Canary Medical, a medical data company focused on the development and commercialization of its ...

February 15, 2024

A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. and Allina Health.

News | Heart Failure

Allina Health Minneapolis Heart Institute is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure

February 12, 2023 — A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully ...

February 12, 2024

ResearcherLate-breaking science from the American Stroke Association’s International Stroke Conference, ISC 2024, reports researchers found an artificial intelligence (AI) system to help guide treatment decisions for stroke patients led to improved stroke care quality and fewer recurrent strokes, heart attacks and vascular death among stroke survivors three months after a stroke.

News | AHA

International Stroke Conference Researcher Finds AI-based System Helped Guide Treatment, Lowered Stroke Recurrence

February 8, 2024 — The latest late-breaking science from the second day of the American Stroke Association’s Internation ...

February 08, 2024

This new document builds off of the previously published Best Practices for Consumer Cardiovascular Technology Solutions in January 2022.

News | ACC

CTA and ACC Collaborate to Tackle Cardiovascular Disease with Technology

February 7, 2024 — The Consumer Technology Association (CTA) and the American College of Cardiology (ACC) are announcing ...

February 07, 2024

New phenomapping tool and clinical score could lead to personalized strategies for patients hospitalized with ADHF

News | Artificial Intelligence

Machine Learning Informs a New Tool to Guide Treatment for Acute Decompensated Heart Failure

February 6, 2024 — A recent study co-authored by Dr. Matthew Segar, a third-year cardiovascular disease fellow at The ...

February 06, 2024

ATTRibute-CM results also demonstrated rapid clinical benefit on the composite endpoint of all-cause mortality (ACM) and CVH in patients treated with acoramidis, with time-to-first event Kaplan-Meier curves separating at month 3 and continuing to diverge steadily through Month 30

News | FDA

BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

February 6, 2024 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

February 06, 2024

In addressing efficacy, harm, and logistics, the study passes all three of the criteria suggested by the American Heart Association guiding the implementation of polygenic risk scores (PRSs) in cardiovascular care

News | Cardiovascular Clinical Studies

Genomics plc Publishes Clinical Trial Results Demonstrating Successful Integration and Clinical Utility of Integrated Risk Scores Combining Polygenic and Clinical Risk of Cardiovascular Disease in NHS Primary Care

February 1, 2024 — Genomics plc (Genomics), a healthcare company aiming to transform health through the power of ...

February 01, 2024

As cardiologists, heart disease patients and the organizations that serve them across the country embark on American Heart Month, ITN has compiled a snapshot of significant cardiovascular disease (CVD) and stroke statistics, along with a review of the atherosclerosis drug market.

Feature | Cardiovascular Education | Christine Book

American Heart Month Puts Spotlight on Cardiovascular Disease and Stroke Statistics

February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country ...

February 01, 2024

Here is a look at the most-read content during the month of January on dicardiology.com

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Top 10: What Viewers Were Reading in January

It is a new year with lots of new content! Here is a look at the most-read content during the month of January on dicard ...

February 01, 2024

Universal risk predictor for cardiovascular disease, suitable for use in both primary and secondary prevention, would streamline risk assessment

News | Heart Failure

Johns Hopkins Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease

January 30, 2024 — Researchers from the Johns Hopkins Bloomberg School of Public Health have developed a single ...

January 30, 2024

News | Sudden Cardiac Arrest

Emergency Cardiovascular Care Impact Goal Outlines 3 Target Needs

January 30, 2024 — Only 10% of people who experience a cardiac arrest survive.[1] In new challenge goals outlined in the ...

January 30, 2024